

**"MPNST Epigenetics"—Response**

Justin Korfhage and David B. Lombard



We thank the authors for their letter (1) and for making these points about our July 2019 *Molecular Cancer Research* review article (2). We acknowledge that they have provided important novel insights, with their new article (3), into a topic discussed in our review regarding potential noncanonical activities of EZH2 in malignant peripheral nerve sheath tumors (MPNST). Wassef and

colleagues present compelling data revealing a marked reduction of EZH2 protein interactions occurring in the absence of SUZ12 in MPNST cells (3). Moreover, gene expression changes occurring in EZH1/2 double-knockout cells closely resemble those in SUZ12-deficient cells. Together, these data support the authors' hypothesis that EZH2 is not mutated in MPNST due to functional redundancy between EZH1 and EZH2, which would necessitate the unlikely deletion of both genes in an MPNST cell to recapitulate the selective advantage of SUZ12 loss. We thank the authors for pointing out their study, which was published concurrently with our review.

Department of Pathology, University of Michigan, Ann Arbor, Michigan.

**Corresponding Author:** David B. Lombard, University of Michigan Medical School, 3015 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48109. Phone: 734-276-9352; Fax: 7349369220; E-mail: davidlom@med.umich.edu

Mol Cancer Res 2019;17:2140

doi: 10.1158/1541-7786.MCR-19-0788

©2019 American Association for Cancer Research.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

Received July 31, 2019; revised August 1, 2019; accepted August 7, 2019; published first October 1, 2019.

**References**

1. Wassef M, Pasmant E, Margueron R. "MPNST epigenetics"—letter. *Mol Cancer Res* 2019;17:2139.
2. Korfhage J, Lombard DB. Malignant peripheral nerve sheath tumors: from epigenome to bedside. *Mol Cancer Res* 2019;17:1417–28.
3. Wassef M, Luscan A, Aflaki S, Zielinski D, Jansen PWTC, Baymaz HI, et al. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. *Proc Natl Acad Sci U S A* 2019;116:6075–80.

# Molecular Cancer Research

## "MPNST Epigenetics"—Response

Justin Korfhage and David B. Lombard

*Mol Cancer Res* 2019;17:2140.

**Updated version** Access the most recent version of this article at:  
<http://mcr.aacrjournals.org/content/17/10/2140>

**Cited articles** This article cites 3 articles, 3 of which you can access for free at:  
<http://mcr.aacrjournals.org/content/17/10/2140.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mcr.aacrjournals.org/content/17/10/2140>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.